Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 3/2025

TREATMENT WITH PARICALCITOL: CLINICAL IMPLICATIONS IN PATIENTS WITH CHRONIC KIDNEY DISEASE

MARIA-DANIELA TĂNĂSESCU 1, ANDREI-MIHNEA ROSU 2*, MĂLINA-GABRIELA TURLACU 3, LAURENȚIU-CRISTIAN ION 4, ALEXANDRU MINCA 1, ANDREEA-LIANA ROSU 5, ELENA IULIANA IONITA 6, DELIA TIMOFTE 7, DORIN IONESCU 1

1 Department of Internal Medicine, Emergency University Hospital Bucharest, Bucharest 050098, Romania, Carol Davila University of Medicine and Pharmacy, 022328, Bucharest, Romania
2 Department of Cardiology, Prof. Dr. Agrippa Ionescu Emergency Hospital, 077015, Balotesti, Ilfov, Romania
3 Department of Cardiology, Clinical Emergency Hospital of Bucharest, Bucharest 014461, Romania
4 Department of Infectious Diseases, “Dr. Victor Babeș” Hospital of Infectious and Tropical Diseases Bucharest, Bucharest 030303, Romania
5 Department of Clinical Pharmacology, Braun, 013714, Bucharest, Romania
6 Department of Pharmacognosy, phytochemistry and phytotherapy, Carol Davila University of Medicine and Pharmacy, 022328, Bucharest, Romania
7 Department of Nephrology, Emergency University Hospital Bucharest, 050098, Bucharest, Romania

Download Full Article PDF

Chronic kidney disease (CKD) is a growing public health concern, often linked to diabetes mellitus and arterial hypertension, and frequently complicated by mineral and bone metabolism disorders due to phosphorus and calcium imbalances. These contribute to cardiovascular calcifications, nephrolithiasis, and bone demineralisation. This review analyses the pharmacological profile and clinical efficacy of paricalcitol in CKD-related mineral and bone disorders. A qualitative assessment was conducted on a series of clinical trials, meta-analyses, and cohort studies, selecting English-language, peer-reviewed studies involving CKD patients (stages 2-5), with or without diabetes and haemodialysis. Paricalcitol was found to reduce parathyroid hormone levels, proteinuria, and inflammatory markers, with favourable safety and tolerability profiles. Emerging evidence indicates potential cardiovascular benefits and disease-modifying effects in diabetic nephropathy, though the impact on creatinine levels and mortality outcomes remains inconclusive and warrants further research.